Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylation patterns and chemosensitivity in NSCLC.

José Luis Ramírez1, M Fernanda Salazar, Jalaj Gupta

  • 1Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

Advances in Experimental Medicine and Biology
|December 14, 2006
PubMed
Summary

Methylation of the 14-3-3sigma gene in serum DNA is a new predictor of longer survival for advanced non-small-cell lung cancer (NSCLC) patients undergoing platinum-based chemotherapy. This biomarker offers a convenient alternative to tumor tissue analysis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro exposure to polystyrene microplastic induces oxidative stress mediated β-cell dysfunction.

Toxicology in vitro : an international journal published in association with BIBRA·2026
Same author

Next-Generation In Vitro Pulmonary Platforms for Respiratory Disease Modelling and Therapeutic Development: Current Advances and Future Prospects.

Medicina (Kaunas, Lithuania)·2026
Same author

Interception of an <i>Apis dorsata</i> swarm with <i>Tropilaelaps mercedesae</i> and <i>Kuzinia morsei</i> mites on a cargo vessel inbound to the United States.

Frontiers in insect science·2026
Same author

Confounding Factors in the Diagnosis of Hereditary Spherocytosis and Gallstone Formation in Related Hemolytic Disorders From a Tertiary Care Center in North India.

Cureus·2025
Same author

Enhanced virulence through genetic engineering of Beauveria bassiana blastospores by overexpression of a cuticle-degrading endochitinase.

Journal of invertebrate pathology·2025
Same author

Mass spectrometry-based discovery and diagnostic validation of T. cruzi antigens in the urine of congenitally infected Chagas Disease patients.

PLoS neglected tropical diseases·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Survival rates for advanced non-small-cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy are highly variable.
  • The 14-3-3sigma gene, a key regulator of the G2/M cell cycle checkpoint, is silenced by methylation.
  • Methylation of 14-3-3sigma may serve as a prognostic indicator for improved patient outcomes.

Purpose of the Study:

  • To investigate whether 14-3-3sigma methylation status in pretreatment serum DNA can predict survival in advanced NSCLC patients.
  • To evaluate the correlation between 14-3-3sigma methylation and treatment response and progression-free survival.

Main Methods:

  • A methylation-specific polymerase chain reaction (PCR) assay was employed to detect 14-3-3sigma methylation in serum DNA from 115 advanced NSCLC patients treated with cisplatin and gemcitabine.

Related Experiment Videos

  • Patient survival, time to progression, and response rates were analyzed in relation to methylation status.
  • Multivariate Cox regression analysis was used to identify independent prognostic factors.

    • Main Results:

    • 14-3-3sigma methylation was detected in 34% of the patients.
    • Patients with methylation-positive serum DNA exhibited significantly longer median survival (15.1 months) compared to methylation-negative patients (9.8 months; P = 0.004).
    • Methylation status and Eastern Cooperative Oncology Group (ECOG) performance status were identified as independent prognostic factors for survival.

    Conclusions:

    • Serum 14-3-3sigma methylation is a novel, independent prognostic biomarker for survival in advanced NSCLC patients treated with platinum-based chemotherapy.
    • This methylation marker can be reliably detected in serum, providing a non-invasive alternative to tumor biopsy.
    • Methylation status is associated with improved survival and potentially longer progression-free survival in this patient cohort.